Michael D. Shultz
Novartis (United States)(US)
Publications by Year
Research Areas
RNA Research and Splicing, RNA and protein synthesis mechanisms, RNA modifications and cancer, HIV/AIDS drug development and treatment, Fullerene Chemistry and Applications
Most-Cited Works
- → Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling(2009)2,068 cited
- → Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases(2016)909 cited
- → Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs(2018)419 cited
- → Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor(2016)286 cited
- → Reactive Nature of Dopamine as a Surface Functionalization Agent in Iron Oxide Nanoparticles(2007)251 cited
- → Preparation of Elemental Cu and Ni Nanoparticles by the Polyol Method: An Experimental and Theoretical Approach(2011)245 cited
- → Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer(2020)210 cited
- → Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters(2013)173 cited
- → Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors(2011)153 cited
- → Dual Allosteric Inhibition of SHP2 Phosphatase(2018)127 cited